Fabrazyme (agalsidase beta)

BIOLOGICAL6 trials

Sponsors

Genzyme, a Sanofi Company

Conditions

Chronic Kidney Disease, Stage IV (Severe)Fabry Disease

Phase 2

A Study of Fabrazyme in Pediatric Patients With Fabry Disease

CompletedNCT00074958

Genzyme, a Sanofi CompanyFabry Disease

Start: 2002-10-31End: 2005-07-31Updated: 2015-04-02

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

CompletedNCT00196716

Genzyme, a Sanofi CompanyFabry Disease

Start: 2003-06-30End: 2007-03-31Updated: 2015-04-03

Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme

TerminatedNCT00837824

Genzyme, a Sanofi CompanyChronic Kidney Disease, Stage IV (Severe), Fabry Disease

Start: 2002-12-31End: 2003-08-31Updated: 2015-04-07

Phase 3

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

CompletedNCT00074971

Genzyme, a Sanofi CompanyFabry Disease

Start: 1999-10-31End: 2004-12-31Target: 58Updated: 2013-12-04

Phase 4

A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease

CompletedNCT00074984

Genzyme, a Sanofi CompanyFabry Disease

Start: 2001-02-28End: 2004-01-31Updated: 2013-12-27

A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency.

WithdrawnNCT00312767

Genzyme, a Sanofi CompanyFabry Disease

Start: 2006-04-30Updated: 2014-02-05